Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

For three decades, doctors went to UpToDate as a search tool. But as OpenEvidence, a startup building an AI-powered version, became one of the hottest

Today, healthcare isn’t what’s driving Oura’s business — technically. The revenue Oura receives from contracts with health plans and providers is “de minimis” right now,

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.